🔗 Share this article

As America proceeds with sweeping revisions to its vaccine schedules, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines during the pandemic and has zeroed in on alleged fatalities after Covid vaccination in her short time at the FDA.

Scheduled Shifts to Childhood Immunization Schedule

Agency leaders planned to unveil major revisions to the childhood vaccine schedule in December, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would put the US out of step with much of the international standard with no evidence for benefit. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A Shift at the Agency

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine centers as Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for ending specific pediatric vaccine recommendations in the US so as to align more like the Danish model, a nation with universal health coverage and a population about the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – usually the domain of Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has little discernible background in drug development, approval processes or leadership, which has been typical for former heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a large organization. She has no expertise in drug approvals.”

Previous directors of CBER would “grasp regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the kind of background that former directors who led CBER have had.”

CDER has an vast workload at the agency, Woodcock stated.

“Everybody just pays attention on the innovative therapies, but the generic drug division clears thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and every single one must be looked after,” she said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the position, which oversees over 5,000 employees. “It is a massive administrative position, if you do it right,” she said.

Response and Disputed Policies

Regarding inquiries about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a representative responded that the “inquiries rely on flawed premises”.

“This background is consistent with the responsibilities of her position,” the official said, noting the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg inherits the commissioner’s recently launched priority voucher program, a contentious rapid drug-approval program that allegedly concerned her predecessors. “How are these drugs being chosen for this voucher program? Who makes the calls?” Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards laxer rules of all drugs, with the exception of shots.”

Public History on Vaccines

With immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard said. She published a research paper using unverified crowd-sourced reports to determine the rate of heart inflammation following Covid vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are riskier than they are.

Among her “policy goals” for the new administration encompassed altering guidelines for recently developed shots and halting “non-essential” vaccines, she said after the election on a podcast. At the agency, Høeg has reportedly suggested preventing teenage boys from receiving COVID-19 vaccines.

“She is an all-around true believer who begins with her conclusions and reverse-engineers to retrofit the data in a very disingenuous, fraudulent way,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|